Type of Mesothelioma:
Localised malignant mesothelioma presenting as an esophageal mass: An unusual manifestation
Radiology Case Reports 2026 May 19 [Link] Kaspar L Yaxley, Tristan Rutland, Thisuri Jayawardena, David Law, Yuranga Weerakkody Abstract Malignant mesothelioma is an aggressive neoplasm arising from mesothelial cells, typically presenting with pleural thickening, pleural effusions, or respiratory symptoms. Dysphagia as a presenting symptom is extremely uncommon, and esophageal involvement is rare. We report a…
Read MoreFeasibility and Outcomes of Cytoreductive Surgery and Hyperthermic Intrathoracic Chemoperfusion for Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 May 28 [Link] Yota Suzuki, Inderpal S Sarkaria, Edra Ha, Ian G Christie, Olugbenga T Okusanya, Omar Awais, Evan T Alicuben, Ryan M Levy, James D Luketich, Neil A Christie Abstract Background: The management of pleural mesothelioma requires a multidisciplinary approach, and hyperthermic intrathoracic chemoperfusion (HITHOC) after surgical cytoreduction…
Read MoreA High-Fidelity Patient-Derived Organoid Platform Recapitulates the Dynamic Metabolic Landscape of Cisplatin Tolerance in Mesothelioma
Cancers 2026 May 7 [Link] Zivile Useckaite, Ashleigh J Hocking, Lauren A Mortimer, John Salamon, Simon Lee, Yazad Irani, Lucy Franzon, Arya L Arul, Sarita Prabhakaran, Sonja Klebe Abstract Background: Pleural mesothelioma (PM) is characterised by often rapid therapeutic failure and chemotherapy resistance. While terminal resistance is well studied, the initial transition into a drug-tolerant…
Read MoreQuercetin-Arctigenin Co-Treatment Induces Mitochondrial Dysfunction and Apoptotic Cell Death Through Metabolic Stress in Malignant Mesothelioma Cells
Life 2026 May 6 [Link] Moon-Kyun Cho, Sang-Han Lee, Hae-Seon Nam, Yoon-Jin Lee Abstract Malignant mesothelioma is an aggressive cancer with limited therapeutic options, highlighting the need for novel strategies targeting metabolic vulnerabilities. Natural polyphenols have gained attention due to their ability to modulate cellular metabolism and apoptosis-related signaling pathways. In this study, we investigated…
Read MoreIncreased Toll-like receptor 9 expression associated with cellular proliferation and poor prognosis in pleural mesothelioma
Journal of Pathology and Translational Medicine 2026 July [Link] Ali Omar Abdelaziz, Dina Moustafa Thabit, Rehab Mohamed Kamal, Hend Moness, Rasha Fouad Ahmed, Mariana Fathy Gayyed, Fatma El Zahraa Ammar Mohamed Abstract Background: Pleural mesothelioma is an aggressive malignancy with a poor prognosis. The epithelioid subtype is the most common and can be challenging to…
Read MoreThe role of microRNAs and competing endogenous RNA regulatory networks in mesothelioma response to immunotherapy
Lung Cancer 2026 July [Link] Farhad Kosari, Paul Baas, Maria Disselhorst, Kim Lauer, Tobias Peikert, Stephen Murphy, Janet Schaefer Klein, Aaron S Mansfield Abstract Assessing the contributions of microRNAs to gene expression regulation and treatment outcomes in malignancies is challenging. Traditional analyses focus on individual microRNAs, overlooking competitive binding among RNA species sharing common microRNAs.…
Read MoreFASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target
Journal of Translational Medicine 2026 May 21 [Link] Valentina Doldi, Chiara Maura Ciniselli, Claudia Aurelio, Enrica Favini, Silvio Marco Veronese, Fabio Bozzi, Shigeki Kusamura, Dario Baratti, Silvia Martini, Paolo Verderio, Marcello Deraco, Marco Folini, Paolo Gandellini, Sandro Pasquali, Nadia Zaffaroni Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive malignancy with limited…
Read MoreMetabolic vulnerabilities in pleural mesothelioma
Oncogenesis 2026 May 20 [Link] Sílvia Plans-Marin, Cristina Muñoz-Pinedo, Ernest Nadal Abstract Mesothelioma is a rare tumour of mesothelial origin that is often diagnosed at advanced stages. Despite recent approval of immunotherapy, the prognosis of mesothelioma remains dismal. Growing evidence links tumour metabolism to the molecular mechanisms driving mesothelioma’s aggressiveness, therapeutic resistance and poor outcomes.…
Read MoreThe Diagnostic Value of Immunohistochemistry and Biomarkers in the Diagnosis of Mesothelioma in Pleural/Peritoneal Effusions
Diagnostic Cytopathology 2026 May 20 [Link] Suzanne M Selvaggi Abstract Background: Mesothelioma is a rare tumor that arises from the serosal cells lining the serous cavities, most commonly the pleura followed by the peritoneum. Presenting symptoms include pleuritic pain and bloody effusions that recur. Although cytologic analysis cannot determine the mesothelial subtype or in situ…
Read MoreA case of diffuse malignant peritoneal mesothelioma: case report and literature review
Irish Journal of Medical Science 2026 May 19 [Link] Qian Zhao, Kangwei Xiong, Qiaoyun Wang, Lijiu Zhang Abstract Introduction: Diffuse malignant peritoneal mesothelioma (DMPM) is a very rare and life-threateningmalignant tumor. Case: We present a report of a rare case of a 70-year-old female patient with emaciation and poor appetite as manifestations. The characteristics of…
Read More
Skip to content